AT8372U2 - Desmopressin umfassende zusammensetzung - Google Patents

Desmopressin umfassende zusammensetzung Download PDF

Info

Publication number
AT8372U2
AT8372U2 AT0020406U AT2042006U AT8372U2 AT 8372 U2 AT8372 U2 AT 8372U2 AT 0020406 U AT0020406 U AT 0020406U AT 2042006 U AT2042006 U AT 2042006U AT 8372 U2 AT8372 U2 AT 8372U2
Authority
AT
Austria
Prior art keywords
desmopressin
comprehensive composition
active ingredient
dosage form
comprehensive
Prior art date
Application number
AT0020406U
Other languages
English (en)
Other versions
AT8372U3 (de
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36218059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT8372(U2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Priority to AT0024906U priority Critical patent/AT8429U3/de
Publication of AT8372U2 publication Critical patent/AT8372U2/de
Publication of AT8372U3 publication Critical patent/AT8372U3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Die vorliegende Erfindung betrifft eine neue pharmazeutische Zusammensetzung als feste Arzneiform, die Desmopressin als therapeutisch wirksamen Bestandteil umfaßt. Sie behandelt Mittel zur Bereitstellung einer erhöhten Haltbarkeit des wirksamen Bestandteils in der Arzneiform.
AT0020406U 2006-03-02 2006-03-16 Desmopressin umfassende zusammensetzung AT8372U3 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT0024906U AT8429U3 (de) 2006-03-02 2006-03-31 Herstellung einer desmopressin umfassenden zusammensetzung

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0600482A SE528446C2 (sv) 2006-03-02 2006-03-02 Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse

Publications (2)

Publication Number Publication Date
AT8372U2 true AT8372U2 (de) 2006-07-15
AT8372U3 AT8372U3 (de) 2007-03-15

Family

ID=36218059

Family Applications (3)

Application Number Title Priority Date Filing Date
AT06005326T ATE394095T1 (de) 2006-03-02 2006-03-15 Stabile desmopressinformulierung in fester form
AT0020406U AT8372U3 (de) 2006-03-02 2006-03-16 Desmopressin umfassende zusammensetzung
AT0043906A AT503320A1 (de) 2006-03-02 2006-03-16 Desmopressin umfassende zusammensetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06005326T ATE394095T1 (de) 2006-03-02 2006-03-15 Stabile desmopressinformulierung in fester form

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT0043906A AT503320A1 (de) 2006-03-02 2006-03-16 Desmopressin umfassende zusammensetzung

Country Status (16)

Country Link
US (1) US20100273709A1 (de)
EP (1) EP1829532B1 (de)
JP (1) JP4976428B2 (de)
AT (3) ATE394095T1 (de)
CY (1) CY1108231T1 (de)
DE (2) DE602006001103D1 (de)
DK (1) DK1829532T3 (de)
ES (1) ES2304033T3 (de)
IL (1) IL193250A0 (de)
NL (1) NL1031397C2 (de)
NO (1) NO20083555L (de)
PL (1) PL1829532T3 (de)
PT (1) PT1829532E (de)
RU (1) RU2340351C1 (de)
SE (1) SE528446C2 (de)
SI (1) SI1829532T1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
PT1530967E (pt) * 2003-11-13 2006-09-29 Ferring Bv Embalagem blister e uma forma de dosagem solida que compreende desmopressina.
CN103304639A (zh) * 2013-06-08 2013-09-18 深圳翰宇药业股份有限公司 一种纯化去氨加压素中间体的方法
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285858A (en) * 1979-10-30 1981-08-25 Mt. Sinai School Of Medicine Of The City University Of N.Y. Vasopressin analogs
US4263283A (en) * 1980-05-16 1981-04-21 Ferring Pharmaceuticals, Inc. Method for prophylaxis and/or treatment of sickle cell disease
SE8306367L (sv) * 1983-11-18 1985-05-19 Ferring Ab Antidiuretiskt verkande farmaceutiskt preparat
US4863737A (en) * 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US7074871B2 (en) * 1992-05-29 2006-07-11 Basell Poliolefine Italia S.R.L. Crystalline polymers of propylene having improved processability in the molten state and process for their preparation
SE9300937L (sv) * 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
SE501677C2 (sv) * 1993-06-18 1995-04-10 Ferring Bv Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel
HU221617B1 (hu) * 1993-06-29 2002-12-28 Ferring B.V. Vizes készítmény dezmopresszin nazális adagolására
US5985835A (en) * 1993-12-23 1999-11-16 Ferring B.V. Desmopressin for nocturia, incontinence and enuresis
ES2149880T3 (es) * 1993-06-29 2000-11-16 Ferring Bv Sintesis de peptidos ciclicos.
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5500413A (en) * 1993-06-29 1996-03-19 Ferring Ab Process for manufacture of 1-deamino-8-D-arginine vasopressin
US5674850A (en) * 1993-12-23 1997-10-07 Ferring Ab High purity desmopressin produced in large single batches
SE9400918L (sv) * 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US5763398A (en) * 1996-06-20 1998-06-09 Ferring B.V. Nasal administration of desmopressin
US5922680A (en) * 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US20060025387A1 (en) * 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
AR014640A1 (es) * 1999-02-23 2001-03-28 Univ Nac Quilmes UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
GB2355454A (en) * 1999-10-20 2001-04-25 Ferring Bv Antidiuretic agents
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
GB0015601D0 (en) * 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US6667277B2 (en) * 2001-08-24 2003-12-23 National Starch And Chemical Investment Holding Corporation Water dispersible starch based physical form modification of agricultural agents
DE60307082T4 (de) * 2002-05-07 2015-04-30 Ferring B.V. In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7094545B2 (en) * 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
ES2243840T3 (es) * 2003-07-25 2005-12-01 Ferring B.V. Composicion farmaceutica de desmopresina como forma farmaceutica solida de dosificacion y metodo para la fabricacion de la misma.
CN1826099B (zh) * 2003-07-25 2010-06-09 凡林有限公司 固体剂型药物组合物及其制造方法
AU2003287591C1 (en) * 2003-11-10 2009-12-10 Serenity Pharmaceuticals Llc Pharmaceutical compositions including low dosages of desmopressin
PT1530967E (pt) * 2003-11-13 2006-09-29 Ferring Bv Embalagem blister e uma forma de dosagem solida que compreende desmopressina.
US7344725B2 (en) * 2003-11-25 2008-03-18 Alcon, Inc. Use of inorganic nanoparticles to stabilize hydrogen peroxide solutions
ES2254858T3 (es) * 2003-12-29 2006-06-16 Ferring B.V. Metodo para preparar una forma farmaceutica solida de desmopresina.
US7018653B2 (en) * 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
RU2007139543A (ru) * 2005-04-22 2009-05-27 Вайет (Us) Производные бензодиоксана и бензодиоксолана и их применение

Also Published As

Publication number Publication date
CY1108231T1 (el) 2014-02-12
SE0600482L (sv) 2006-11-14
DK1829532T3 (da) 2008-08-04
ES2304033T3 (es) 2008-09-01
ATE394095T1 (de) 2008-05-15
JP4976428B2 (ja) 2012-07-18
SE528446C2 (sv) 2006-11-14
SI1829532T1 (sl) 2008-08-31
IL193250A0 (en) 2011-08-01
EP1829532B1 (de) 2008-05-07
NL1031397A1 (nl) 2006-05-08
JP2009528312A (ja) 2009-08-06
RU2340351C1 (ru) 2008-12-10
DE602006001103D1 (de) 2008-06-19
RU2007107368A (ru) 2008-09-10
AT8372U3 (de) 2007-03-15
NO20083555L (no) 2008-08-18
US20100273709A1 (en) 2010-10-28
EP1829532A1 (de) 2007-09-05
AT503320A1 (de) 2007-09-15
PL1829532T3 (pl) 2008-09-30
PT1829532E (pt) 2009-02-13
NL1031397C2 (nl) 2006-09-18
DE202006004746U1 (de) 2006-06-29

Similar Documents

Publication Publication Date Title
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2008000592A1 (es) Compuestos derivados de pirrol sustituido, supresores de la secrecion de acidos; composicion farmaceutica; y uso en el tratamiento o profilaxis en enfermedades tales como ulcera peptica, gastritis, esofagitis, entre otras.
MX2011008171A (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
PH12013502192A1 (en) Antibodies against human angiopoietin 2
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
CL2008001994A1 (es) Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CL2008001025A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer.
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20084850L (no) MGLUR5 modulatorer I
CL2008000875A1 (es) Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras.
CL2007002377A1 (es) Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
CO6300844A2 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
CL2007003832A1 (es) Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2007002376A1 (es) Compuestos derivados de pirrol sustituido; proceso de preparacion; composicion farmaceutica; y uso en enfermedades bacterianas.
WO2010021607A3 (en) Pharmaceutical formulation
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.

Legal Events

Date Code Title Description
HA9K Mention of the inventor

Inventor name: OLSSON LARS-ERIK, MALMOE (SE); NILSSON ANDERS, LUND

MA9K Ceased due to renunciation

Effective date: 20071023